Press release
Jan 28, 2014

Sosei announces the transfer of Japan marketing authorization for NorLevo® TABLETS 0.75mg to ASKA Pharmaceuticals

Tokyo, Japan – 28 January 2014: Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd. (“Sosei K.K.”), its wholly owned Japanese subsidiary, has agreed to transfer the Japan approved marketing authorization (MA) for NorLevo® TABLETS 0.75mg (“NorLevo”) to ASKA Pharmaceutical Co., Ltd (“ASKA”) starting from 27 January 2014.

NorLevo is an oral emergency contraceptive, which is taken within 72 hours after unprotected sexual intercourse or contraceptive failure to prevent unwanted pregnancy. In 2011, Sosei was granted approval for NorLevo in Japan and has since been using ASKA’s network for distribution. MA transfer to ASKA will enable Sosei K.K. to address the need for redistribution of internal resources and improve overall performance. Under the terms of the agreement with ASKA, Sosei K.K. will continue to receive a part of NorLevo revenue until 2020.

Sosei K.K. will continue to enhance corporate value by focusing effort on development of SO-1105, in-licensing and development of new products.